Arlesheim, Switzerland
Arlesheim, Switzerland

Time filter

Source Type

PubMed | Bundesverband der Arzneimittel Hersteller e.V. BAH, Weleda AG, PhytoLab GmbH & Co. KG and WALA Heilmittel GmbH
Type: | Journal: Pharmeuropa bio & scientific notes | Year: 2016

In the context of a revision of the European Pharmacopoeia (Ph. Eur.) general monograph Essential oils (2098), the need to include a test for pesticides is being discussed. According to published literature, some oils, mainly those produced by cold pressing (e.g. citrus oils), can contain relevant amounts of pesticide residues, whereas distilled oils showed positive findings in only a few cases. Recent evaluation of a database containing 127 517 sets of data compiled over 8 years, showed positive results in 1 150 cases (0.90 per cent), and the limits of Ph. Eur. general chapter 2.8.13 Pesticide residues or Regulation (EC) 396/2005, both applicable to herbal drugs, were exceeded in 392 cases (0.31 per cent, equivalent to 34.1 per cent of the positive results), particularly in cases of oils produced by cold pressing. From these results, it can be concluded that a general test on pesticides in the Ph. Eur. general monograph on essential oils is not required for most oils used in medicinal products. Therefore, it is proposed to limit the testing of essential oils for pesticide residues to those cases where potential residues are more of a concern, either due to the type of production process or to those processes where pesticides are actively used during cultivation of the plant (e.g. as documented according to Good Agricultural and Collection Practice (GACP)). Furthermore, in order to assess any potential risk, an approach using the Acceptable Daily Intake (ADI) can be made.


News Article | November 18, 2016
Site: www.newsmaker.com.au

This report studies sales (consumption) of Herbal in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering  NBTY(US)  Tsumura(JP)  Weleda(CH)  DSM?NL?  Nature's Sunshine Products(US)  Madaus(DE)  Nutraceutical(US)  Arkopharma(FR)  Schwabe(DE)  Ricola(CH)  Blackmores(AU)  Dabur(IN)  Herbal Africa?ZA)  Pharma Nord APS(DM)  SIDO MUNCUL(ID)  Nature's Answer (US)  TwinLab(US)  Pharmavite(US)b  Arizona Natural(US)  Potter's Herbals(UK)  Tongrentang(CN)  TASLY(CN)  Yunnan Baiyao(CN)  Sanjiu(CN)  Zhongxin(CN) Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Herbal in these regions, from 2011 to 2021 (forecast), like  United States  China  Europe  Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into  Mono-Herb Type  Multi-Herb Type  Type III Split by applications, this report focuses on sales, market share and growth rate of Herbal in each application, can be divided into  Pharmaceutical Industry  Health Care Industry  Others Global Herbal Sales Market Report 2016  1 Herbal Overview  1.1 Product Overview and Scope of Herbal  1.2 Classification of Herbal  1.2.1 Mono-Herb Type  1.2.2 Multi-Herb Type  1.2.3 Type III  1.3 Application of Herbal  1.3.1 Pharmaceutical Industry  1.3.2 Health Care Industry  1.3.3 Others  1.4 Herbal Market by Regions  1.4.1 United States Status and Prospect (2011-2021)  1.4.2 China Status and Prospect (2011-2021)  1.4.3 Europe Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.5 Global Market Size (Value and Volume) of Herbal (2011-2021)  1.5.1 Global Herbal Sales and Growth Rate (2011-2021)  1.5.2 Global Herbal Revenue and Growth Rate (2011-2021) 7 Global Herbal Manufacturers Analysis  7.1 NBTY(US)  7.1.1 Company Basic Information, Manufacturing Base and Competitors  7.1.2 Herbal Product Type, Application and Specification  7.1.2.1 Type I  7.1.2.2 Type II  7.1.3 NBTY(US) Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.1.4 Main Business/Business Overview  7.2 Tsumura(JP)  7.2.1 Company Basic Information, Manufacturing Base and Competitors  7.2.2 129 Product Type, Application and Specification  7.2.2.1 Type I  7.2.2.2 Type II  7.2.3 Tsumura(JP) Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.2.4 Main Business/Business Overview  7.3 Weleda(CH)  7.3.1 Company Basic Information, Manufacturing Base and Competitors  7.3.2 146 Product Type, Application and Specification  7.3.2.1 Type I  7.3.2.2 Type II  7.3.3 Weleda(CH) Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.3.4 Main Business/Business Overview  7.4 DSM?NL?  7.4.1 Company Basic Information, Manufacturing Base and Competitors  7.4.2 Nov Product Type, Application and Specification  7.4.2.1 Type I  7.4.2.2 Type II  7.4.3 DSM?NL? Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.4.4 Main Business/Business Overview  7.5 Nature's Sunshine Products(US)  7.5.1 Company Basic Information, Manufacturing Base and Competitors  7.5.2 Product Type, Application and Specification  7.5.2.1 Type I  7.5.2.2 Type II  7.5.3 Nature's Sunshine Products(US) Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.5.4 Main Business/Business Overview  7.6 Madaus(DE)  7.6.1 Company Basic Information, Manufacturing Base and Competitors  7.6.2 Million USD Product Type, Application and Specification  7.6.2.1 Type I  7.6.2.2 Type II  7.6.3 Madaus(DE) Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.6.4 Main Business/Business Overview  7.7 Nutraceutical(US)  7.7.1 Company Basic Information, Manufacturing Base and Competitors  7.7.2 Pharmaceuticals Product Type, Application and Specification  7.7.2.1 Type I  7.7.2.2 Type II  7.7.3 Nutraceutical(US) Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.7.4 Main Business/Business Overview  7.8 Arkopharma(FR)  7.8.1 Company Basic Information, Manufacturing Base and Competitors  7.8.2 Product Type, Application and Specification  7.8.2.1 Type I  7.8.2.2 Type II  7.8.3 Arkopharma(FR) Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.8.4 Main Business/Business Overview  7.9 Schwabe(DE)  7.9.1 Company Basic Information, Manufacturing Base and Competitors  7.9.2 Product Type, Application and Specification  7.9.2.1 Type I  7.9.2.2 Type II  7.9.3 Schwabe(DE) Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.9.4 Main Business/Business Overview  7.10 Ricola(CH)  7.10.1 Company Basic Information, Manufacturing Base and Competitors  7.10.2 Product Type, Application and Specification  7.10.2.1 Type I  7.10.2.2 Type II  7.10.3 Ricola(CH) Herbal Sales, Revenue, Price and Gross Margin (2011-2016)  7.10.4 Main Business/Business Overview  7.11 Blackmores(AU)  7.12 Dabur(IN)  7.13 Herbal Africa?ZA)  7.14 Pharma Nord APS(DM)  7.15 SIDO MUNCUL(ID)  7.16 Nature's Answer (US)  7.17 TwinLab(US)  7.18 Pharmavite(US)b  7.19 Arizona Natural(US)  7.20 Potter's Herbals(UK)  7.21 Tongrentang(CN)  7.22 TASLY(CN)  7.23 Yunnan Baiyao(CN)  7.24 Sanjiu(CN)  7.25 Zhongxin(CN)


Grundemann C.,Albert Ludwigs University of Freiburg | Papagiannopoulos M.,WELEDA AG | Lamy E.,Albert Ludwigs University of Freiburg | Mersch-Sundermann V.,Albert Ludwigs University of Freiburg | Huber R.,Albert Ludwigs University of Freiburg
Phytomedicine | Year: 2011

Introduction: Gencydo®, a combination of lemon (Citrus limon) juice and aqueous quince (Cydonia oblonga) extract has been used traditionally in anthroposophical medicine for treating patients with allergic rhinitis or asthma. Because there are no reports about the mode of action, we investigated the anti-allergic effects of this preparation in vitro by using cell lines and primary cells in various biological and immunological endpoints. Materials and methods: The release of soluble mediators from basophilic cells, mast cells and lung epithelial cells, which are essential for the initiation of early- and late-phase allergic reactions, was analyzed in relation to the synthetic anti-allergic drugs azelastine and dexamethasone. In addition, the impact of Gencydo® on the viability and activation of GM-CSF-activated eosinophil granulocytes was investigated. Results and discussion: Gencydo® reduced the degranulation and histamine release of IgE-activated basophilic cells and mast cells and inhibited the IgE- and PMA/A23187-induced increases in IL-8, TNF-α and GM-CSF production in mast cells. The effects were comparable to that of the used concentration of azelastine and dexamethasone. Furthermore, Gencydo® partially blocked eotaxin release from human bronchial epithelial cells, but has no impact on the viability and activation of GM-CSF-activated eosinophil granulocytes. In conclusion, these results give a rational base for the topical use of Gencydo® in treatment of allergic disorders through the down regulation of soluble mediators, which are essential for the initiation and maintenance of allergic reactions. © 2010 Elsevier GmbH. All rights reserved.


Simoes-Wust A.P.,Paracelsus Hospital | Jeschke E.,Havelhoehe Research Institute | Mennet M.,Weleda AG | Schnelle M.,Weleda AG | And 2 more authors.
Forschende Komplementarmedizin | Year: 2012

Background: The use of preparations from Bryophyllum pinnatum for tocolysis (or to arrest labor) is supported by observations obtained mainly at empirical level, but also by preclinical experiments performed with uterus strips and myometrium cell lines. Furthermore, a retrospective matched-pair study revealed good tolerability and effectiveness. In anthroposophic medicine, however, Bryophyllum species are used for a broad spectrum of diagnoses. Here, we characterize the prescribing pattern of Bryophyllum preparations in a network of anthroposophic physicians in Germany. Methods: 38 primary-care physicians in Germany participated in the EvaMed network, a multi-center observational study. They documented anonymized prescriptions, diagnoses and demographic data (age and gender) for each consecutive patient between 01.01.2004 and 01.01.2010. Diagnoses were coded according to the 10th revision of the International Classification of Diseases (ICD-10). In the present analysis, all prescriptions of any Bryophyllum preparation in the resulting data bank were identified and the corresponding diagnoses were analyzed retrospectively. Results: A total of 4,038 prescriptions of Bryophyllum preparations were identified in the EvaMed data bank. A variety of preparations could be found, 77.7% of which were prepared from Bryophyllum plants exclusively and 22.5% were combinations. Bryophyllum preparations were often prescribed to treat 'mental and behavioral disorders' (ICD-10 F00-F99, 35.7%) and 'diseases of the skin and subcutaneous tissue' (L00-L99, 16.0%), followed by 'symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified diseases' (R00-R99, 15.2%) and 'diseases of the nervous system' (G00-G99, 9.7%). Conclusion: By revealing the use of Bryophyllum preparations in so many other indications than preterm delivery, our data clearly show the urgent need to conduct additional clinical trials. © 2012 S. Karger AG, Basel.


Zimmermann B.F.,University of Bonn | Zimmermann B.F.,Institute Prof. Dr. Kurz GmbH | Woelwer-Rieck U.,University of Bonn | Papagiannopoulos M.,University of Bonn | Papagiannopoulos M.,Weleda AG
Food Analytical Methods | Year: 2012

Stevia rebaudiana Bertoni contains several steviol glycosides with sweet flavour. They all are sweeter than sucrose (up to factor 450). The various steviol glycosides are difficult to separate by reversed-phase chromatography. In this paper, five different hydrophilic liquid interaction chromatography columns are characterized using isocratic elution (5-20% water in acetonitrile with buffer or formic acid). Separation of the steviol glycosides is possible with all but one of the tested columns, but the robustness of the separation against changes of buffer concentration and percentage of water differ. Aqueous percentage and ion strength of the eluent are the main factors to be optimized in method development. © 2011 Springer Science+Business Media, LLC.


Background: Functional cardiovascular disorders (FCD) can be attributed to around 25-40% of all heart patients, i.e. organic causes are not detectable. Characteristic symptoms are tachycardia, palpitations, cardiac arrhythmia, hyperventilation, vertigo, vasovagal syncopes and sleep disorders, with the latter being a problem of its own. Disturbed vegetative rhythms form the basis of these diseases. The medicinal product Cardiodoron counteracts the dysfunctional vegetative rhythmicity with 3 medicinal plants - Primula veris (common cowslip), Hyoscyamus niger (black henbane) and Onopordum acanthium (cotton thistle). Patients and Methods: By means of a prospective, multicentre, non-interventional study, the development of disease-specific disorders during treatment with Cardiodoron (drops) was supposed to be shown. Between September 2009 and March 2012, 92 physicians documented 501 patients suffering from functional cardiovascular and/or sleep disorders who have been treated with Cardiodoron for 3-6 months. After an initial examination, a final examination after 90 (± 10) days and, in case of continuation of therapy, a follow-up examination after 90 (± 10) days were carried out. Besides 30 symptoms assessed by the physicians, the patients rated their condition on the basis of the complaints list according to v. Zerssen (B-L and B-L') and the Pittsburgh Sleep Quality Index (PSQI) according to Buysse. Results: The severity of functional cardiovascular disorders as well as sleep disorders was significantly reduced. The same applies for all of the documented 30 disease-specific symptoms. Furthermore, the total score of the complaints list was significantly reduced as well as the PSQI. The largest effect regarding all parameters was detectable after 3 months. Continuation of Cardiodoron therapy stabilised the symptomatology once more and resulted in further improvement. On average, patients reported initial improvement after 13 days of treatment. Tolerability was almost consistently assessed with 'very good / good'. Accordingly, the acceptance of the preparation by the patients was good, which resulted in a very good compliance of 70%. 52% of the patients used additional therapies. Conclusions: Cardiodoron shows positive effects in medical practice; it is a well-tolerated medicinal product for treatment of functional cardiovascular and/or sleep disorders with or without concomitant therapies. © 2013 S. Karger GmbH, Freiburg.


News Article | November 1, 2016
Site: www.newsmaker.com.au

The global organic cosmetics market was valued at nearly US$ 40 billion in 2015, and by 2020, it is expected to reach US$ 66 billion, increasing at a CAGR of over 10%. ASEAN, an emerging market for organic cosmetics, is expected to witness high demand, driven a number of factors on which information is offered in the report, “Organic Cosmetics Market: ASEAN Industry Analysis and Opportunity Assessment, 2014-2020”. Rising awareness about the potential side effects of synthetic cosmetics is a key factor driving increased demand for organic cosmetics. Positive perception towards organic cosmetics, availability of wide range of organic cosmetics, and emergence of a strong middle class in ASEAN are the other key regions fuelling demand. On account of these factors, the organic cosmetics market in ASEAN is expected to increase at over 9% through 2020 and reach US$ 4.4 billion in revenues. High cost, limited shelf life, and lack of standard certification have been identified as key challenges to the growth of the ASEAN organic cosmetics market. There is an urgent need for establishing rigorous certification standards, so that only those reliable and genuine brands are able to launch their products in the market. On the basis of product type, the ASEAN organic cosmetics market can be broadly segmented into skin care, hair care, make up, fragrances, and toiletries. Among these, organic hair care products accounted for the highest revenue share of the market in 2015. Valued at US$ 780 million in 2015, demand for organic hair care products in ASEAN is expected to reach US$ 1.24 billion by the end of 2020. Skin care is the second-highest product type on the basis of revenues, valued at US$ 671 million in 2015. This segment is expected to expand at a CAGR of 9.7% through 2020, and surpass US$ 1 billion in revenues by 2020. Organic fragrances and toiletries are also expected to expand at healthy CAGRs through the forecast period. In terms of revenues, Thailand, Indonesia, and Philippines are the three largest markets for organic cosmetics in ASEAN. Thailand, the largest market for organic cosmetics in ASEAN, accounted for nearly 30% revenue share of the overall market in 2015. Valued at US$ 809 million in 2015, the Thailand organic cosmetics market is expected to expand at 9.4% CAGR to reach US$ 1.29 billion in revenues by 2020. Beauty specialist salon and pharmacy/drugstores are the two largest distribution channels in Thailand, collectively accounting for nearly 57% of overall sales. Indonesia is the second largest market, with total revenues totalling US$ 671 million in 2015. However, the Indonesia organic cosmetics market is expected to expand at slightly lower CAGR than rest of ASEAN countries. Beauty salon and e-commerce websites are the two largest distribution channels for organic cosmetics in Indonesia. The Philippines organic cosmetics market was valued at US$ 552 million in 2015. General merchandise retailers account for a high percentage of total sales of organic cosmetics in Philippines. The leading players in the ASEAN organic cosmetics market are Estee Lauder Inc., Le Groupe L'OCCITANE, L'Oreal Group, Weleda Inc., W.S. Badger Company Inc.


Personal care and cosmetics are mixtures of chemical compounds or organic ingredients, used to enhance the overall appearance or are used for personal hygiene. Organic personal care and cosmetic products mainly comprise plant ingredients and do not contain chemicals such as parabens, phthalates, aluminum salts and petrochemicals, which are potentially harmful to an individuals health. Increasing beauty consciousness and health awareness are prime factors boosting the market growth. Moreover, operating players in the market have been putting numerous efforts into launching several products in the market, thereby supplementing the market growth. Stringent government regulations especially in developed countries have enforced the companies operating in personal care and cosmetics market to introduce organic products over chemical products. As a result, operating companies have developed organic personal care and cosmetics products, thereby increasing overall consumption of organic personal care and cosmetics in the recent past. Increasing consciousness about personal appearance and overall health awareness contribute to the growth of organic personal care and cosmetics industry. Moreover, increasing disposable income coupled with improved standards of living drive the adoption of personal care and organic cosmetics products. However, brief shelf life of organic personal care and cosmetics and availability of advanced beauty treatments are restricting the growth of the market. Government support and regulation would offer several growth opportunities to the operating players operating in the market. Organic personal care and cosmetics products market is segmented on the basis of product type, distribution channel and geography. The product type segment is further classified as skin care, hair care, oral care, makeup cosmetics and others (deodorants, feminine hygiene products and hand hygiene). Among all types, the skin care segment dominated the market in 2015. Retail sales and online sales are two broad classifications based on distribution channel. Retail channel was the highest revenue-generating segment in 2015 and is expected to maintain its position during the forecast period. However, online channel would grow rapidly during the forecast period. Based on geography, the market is segmented into North America, Europe, Asia-Pacific and LAMEA. The prominent players analyzed in this report include L'Occitane en Provence, LOral International, Arbonne International, LLC, Burt's Bee, Este Lauder Companies Inc., Amway Corporation, Oriflame Cosmetics S.A., Yves Rocher, Weleda, and Aubrey Organics. Chapter: 7 COMPANY PROFILES      7.1 L'Occitane en Provence (L'Occitane Group)        7.1.1 Company overview        7.1.2 Company snapshot        7.1.3 Business performance        7.1.4 Strategic moves and developments        7.1.5 SWOT analysis of L'Occitane en Provence      7.2 LOreal International        7.2.1 Company overview        7.2.2 Company snapshot        7.2.3 Business performance        7.2.4 Strategic moves and developments        7.2.5 SWOT analysis of LOreal International      7.3 Arbonne International, LLC        7.3.1 Company overview        7.3.2 Company snapshot        7.3.3 Strategic moves and developments        7.3.4 SWOT analysis of Arbonne International, LLC      7.4 Burt's Bees        7.4.1 Company overview        7.4.2 Company snapshot        7.4.3 Business performance        7.4.4 Strategic moves and developments        7.4.5 SWOT analysis of Burt's Bees      7.5 Estee Lauder Companies Inc.        7.5.1 Company overview        7.5.2 Company snapshot        7.5.3 Business performance        7.5.4 Strategic moves and developments        7.5.5 SWOT analysis of Estee Lauder Companies Inc.      7.6 Amway Corporation        7.6.1 Company overview        7.6.2 Company snapshot        7.6.3 Business performance        7.6.4 Strategic moves and developments        7.6.5 SWOT analysis of Amway Corporation      7.7 Oriflame Cosmetics S.A.        7.7.1 Company overview        7.7.2 Company snapshot        7.7.3 Business performance        7.7.4 Strategic moves and developments        7.7.5 SWOT analysis of Oriflame Cosmetics S.A.      7.8 Yves Rocher        7.8.1 Company overview        7.8.2 Company snapshot        7.8.3 Strategic moves and developments        7.8.4 SWOT analysis of Yves Rocher      7.9 Weleda        7.9.1 Company overview        7.9.2 Company snapshot        7.9.3 Business performance        7.9.4 Strategic moves and developments        7.9.5 SWOT analysis of Weleda      7.10 Aubrey Organics        7.10.1 Company overview        7.10.2 Company snapshot        7.10.3 SWOT analysis of Aubrey Organics


News Article | November 23, 2016
Site: www.newsmaker.com.au

This report studies Baby Skin Care Cream in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering  Johnson & Johnson  Pigeon  YMJ  Jahwa  Sebamed  Mustela  Elsker  Frog Prince Daily Chemical Co., Ltd.  Carefor  Blonde Rabbi Baby Supplies Co., Ltd  Weleda?  Penaten  Sanosan Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Baby Skin Care Cream in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Natural  Synthetic  Type III Split by application, this report focuses on consumption, market share and growth rate of Baby Skin Care Cream in each application, can be divided into  Family  Center For the Month  Nursery Global Baby Skin Care Cream Market Research Report 2016  1 Baby Skin Care Cream Market Overview  1.1 Product Overview and Scope of Baby Skin Care Cream  1.2 Baby Skin Care Cream Segment by Type  1.2.1 Global Production Market Share of Baby Skin Care Cream by Type in 2015  1.2.2 Natural  1.2.3 Synthetic  1.2.4 Type III  1.3 Baby Skin Care Cream Segment by Application  1.3.1 Baby Skin Care Cream Consumption Market Share by Application in 2015  1.3.2 Family  1.3.3 Center For the Month  1.3.4 Nursery  1.4 Baby Skin Care Cream Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Baby Skin Care Cream (2011-2021) 7 Global Baby Skin Care Cream Manufacturers Profiles/Analysis  7.1 Johnson & Johnson  7.1.1 Company Basic Information, Manufacturing Base and Its Competitors  7.1.2 Baby Skin Care Cream Product Type, Application and Specification  7.1.2.1 Type I  7.1.2.2 Type II  7.1.3 Johnson & Johnson Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016) 7.1.4 Main Business/Business Overview  7.2 Pigeon  7.2.1 Company Basic Information, Manufacturing Base and Its Competitors  7.2.2 Baby Skin Care Cream Product Type, Application and Specification  7.2.2.1 Type I  7.2.2.2 Type II  7.2.3 Pigeon Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016)  7.2.4 Main Business/Business Overview  7.3 YMJ  7.3.1 Company Basic Information, Manufacturing Base and Its Competitors  7.3.2 Baby Skin Care Cream Product Type, Application and Specification  7.3.2.1 Type I  7.3.2.2 Type II  7.3.3 YMJ Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016)  7.3.4 Main Business/Business Overview  7.4 Jahwa  7.4.1 Company Basic Information, Manufacturing Base and Its Competitors  7.4.2 Baby Skin Care Cream Product Type, Application and Specification  7.4.2.1 Type I  7.4.2.2 Type II  7.4.3 Jahwa Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016)  7.4.4 Main Business/Business Overview  7.5 Sebamed  7.5.1 Company Basic Information, Manufacturing Base and Its Competitors  7.5.2 Baby Skin Care Cream Product Type, Application and Specification  7.5.2.1 Type I  7.5.2.2 Type II  7.5.3 Sebamed Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016)  7.5.4 Main Business/Business Overview  7.6 Mustela  7.6.1 Company Basic Information, Manufacturing Base and Its Competitors  7.6.2 Baby Skin Care Cream Product Type, Application and Specification  7.6.2.1 Type I  7.6.2.2 Type II  7.6.3 Mustela Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016)  7.6.4 Main Business/Business Overview  7.7 Elsker  7.7.1 Company Basic Information, Manufacturing Base and Its Competitors  7.7.2 Baby Skin Care Cream Product Type, Application and Specification  7.7.2.1 Type I  7.7.2.2 Type II  7.7.3 Elsker Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016)  7.7.4 Main Business/Business Overview  7.8 Frog Prince Daily Chemical Co., Ltd.  7.8.1 Company Basic Information, Manufacturing Base and Its Competitors  7.8.2 Baby Skin Care Cream Product Type, Application and Specification  7.8.2.1 Type I  7.8.2.2 Type II  7.8.3 Frog Prince Daily Chemical Co., Ltd. Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016)  7.8.4 Main Business/Business Overview  7.9 Carefor  7.9.1 Company Basic Information, Manufacturing Base and Its Competitors  7.9.2 Baby Skin Care Cream Product Type, Application and Specification  7.9.2.1 Type I  7.9.2.2 Type II  7.9.3 Carefor Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016)  7.9.4 Main Business/Business Overview  7.10 Blonde Rabbi Baby Supplies Co., Ltd  7.10.1 Company Basic Information, Manufacturing Base and Its Competitors  7.10.2 Baby Skin Care Cream Product Type, Application and Specification  7.10.2.1 Type I  7.10.2.2 Type II  7.10.3 Blonde Rabbi Baby Supplies Co., Ltd Baby Skin Care Cream Production, Revenue, Price and Gross Margin (2015 and 2016)  7.10.4 Main Business/Business Overview  7.11 Weleda?  7.12 Penaten  7.13 Sanosan


News Article | February 17, 2017
Site: marketersmedia.com

This report studies Herbal in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Herbal in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast Asia India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Split by application, this report focuses on consumption, market share and growth rate of Herbal in each application, can be divided into Ginkgo biloba Echinacea Chamomile (Chamomilla recutita) St John’s wort (Hypericum perforatum) Valerian Dong quai Astragalus Licorice At any Query @ https://www.wiseguyreports.com/enquiry/975021-global-herbal-market-research-report-2017 Table of Contents Global Herbal Market Research Report 2017 1 Herbal Market Overview 1.1 Product Overview and Scope of Herbal 1.2 Herbal Segment by Type 1.2.1 Global Production Market Share of Herbal by Type in 2015 1.2.2 Type I 1.2.3 Type II 1.3 Herbal Segment by Application 1.3.1 Herbal Consumption Market Share by Application in 2015 1.3.2 Ginkgo biloba 1.3.3 Echinacea 1.3.4 Chamomile (Chamomilla recutita) 1.3.5 St John’s wort (Hypericum perforatum) 1.3.6 Valerian 1.3.7 Dong quai 1.3.8 Astragalus 1.3.9 Licorice 1.4 Herbal Market by Region 1.4.1 North America Status and Prospect (2012-2022) 1.4.2 Europe Status and Prospect (2012-2022) 1.4.3 China Status and Prospect (2012-2022) 1.4.4 Japan Status and Prospect (2012-2022) 1.4.5 Southeast Asia Status and Prospect (2012-2022) 1.4.6 India Status and Prospect (2012-2022) 1.5 Global Market Size (Value) of Herbal (2012-2022) 7 Global Herbal Manufacturers Profiles/Analysis 7.1 Tsumura 7.1.1 Company Basic Information, Manufacturing Base and Its Competitors 7.1.2 Herbal Product Type, Application and Specification 7.1.2.1 Product A 7.1.2.2 Product B 7.1.3 Tsumura Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.1.4 Main Business/Business Overview 7.2 Schwabe 7.2.1 Company Basic Information, Manufacturing Base and Its Competitors 7.2.2 Herbal Product Type, Application and Specification 7.2.2.1 Product A 7.2.2.2 Product B 7.2.3 Schwabe Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.2.4 Main Business/Business Overview 7.3 Madaus 7.3.1 Company Basic Information, Manufacturing Base and Its Competitors 7.3.2 Herbal Product Type, Application and Specification 7.3.2.1 Product A 7.3.2.2 Product B 7.3.3 Madaus Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.3.4 Main Business/Business Overview 7.4 Weleda 7.4.1 Company Basic Information, Manufacturing Base and Its Competitors 7.4.2 Herbal Product Type, Application and Specification 7.4.2.1 Product A 7.4.2.2 Product B 7.4.3 Weleda Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.4.4 Main Business/Business Overview 7.5 Blackmores 7.5.1 Company Basic Information, Manufacturing Base and Its Competitors 7.5.2 Herbal Product Type, Application and Specification 7.5.2.1 Product A 7.5.2.2 Product B 7.5.3 Blackmores Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.5.4 Main Business/Business Overview 7.6 Arkopharma 7.6.1 Company Basic Information, Manufacturing Base and Its Competitors 7.6.2 Herbal Product Type, Application and Specification 7.6.2.1 Product A 7.6.2.2 Product B 7.6.3 Arkopharma Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.6.4 Main Business/Business Overview 7.7 SIDO MUNCUL 7.7.1 Company Basic Information, Manufacturing Base and Its Competitors 7.7.2 Herbal Product Type, Application and Specification 7.7.2.1 Product A 7.7.2.2 Product B 7.7.3 SIDO MUNCUL Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.7.4 Main Business/Business Overview 7.8 Arizona Natural 7.8.1 Company Basic Information, Manufacturing Base and Its Competitors 7.8.2 Herbal Product Type, Application and Specification 7.8.2.1 Product A 7.8.2.2 Product B 7.8.3 Arizona Natural Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.8.4 Main Business/Business Overview 7.9 Dabur 7.9.1 Company Basic Information, Manufacturing Base and Its Competitors 7.9.2 Herbal Product Type, Application and Specification 7.9.2.1 Product A 7.9.2.2 Product B 7.9.3 Dabur Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.9.4 Main Business/Business Overview 7.10 Herbal Africa 7.10.1 Company Basic Information, Manufacturing Base and Its Competitors 7.10.2 Herbal Product Type, Application and Specification 7.10.2.1 Product A 7.10.2.2 Product B 7.10.3 Herbal Africa Herbal Production, Revenue, Price and Gross Margin (2015 and 2016) 7.10.4 Main Business/Business Overview 7.11 Nature’s Answer 7.12 Bio-Botanica 7.13 Potter’s 7.14 Zand 7.15 Nature Herbs 7.16 Imperial Ginseng 7.17 Yunnan Baiyao 7.18 Tongrentang 7.19 TASLY 7.20 Zhongxin 7.21 Kunming Pharma 7.22 Sanjiu 7.23 JZJT 7.24 Guangzhou Pharma 7.25 Taiji 7.26 Haiyao For more information, please visit https://www.wiseguyreports.com/sample-request/975021-global-herbal-market-research-report-2017

Loading Weleda AG collaborators
Loading Weleda AG collaborators